Stephen Kopecky, MD
Cardiovascular Disease · Rochester, MNNPI 1225008329
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,958 of the $29,768 with a category attached, or 97.3%. 8 manufacturers reported payments, led by Amgen at 52.6% of the total.
Across 26 payments — averaging $1144.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$16K
- AstraZeneca$7K
- Roche Diabetes Care GmbH$3K
- Madrigal Pharmaceuticals$2K
- Sanofi US Services Inc.$2K
- Merck$500
- plus $48 from 2 others
Across 4 payments — averaging $53,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$213K
What the payments were for
- Consulting fees$28,95897%
- Travel & lodging$1621%
- Food & beverage$6372%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $15,657 |
| AstraZeneca | 5 | $6,713 |
| Roche Diabetes Care GmbH | 1 | $3,000 |
| Madrigal Pharmaceuticals | 5 | $2,100 |
| Sanofi US Services Inc. | 4 | $1,750 |
| Merck | 1 | $500 |
| Akcea Therapeutics, Inc. | 1 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,768 in reported general payments places this provider in the 85th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 233 | $223,581 |
| Praluent PenAlirocumab | 37 | $34,804 |
| EliquisApixaban | 22 | $19,604 |
| Ezetimibe | 110 | $1,845 |
| Rosuvastatin Calcium | 105 | $790 |
| Metoprolol Succinate | 41 | $401 |
| Atorvastatin Calcium | 47 | $372 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 14 | $300 |
| ClopidogrelClopidogrel Bisulfate | 19 | $160 |
| Hydrochlorothiazide | 16 | $123 |
| Amlodipine Besylate | 11 | $84 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Rochester
- Srijoy MahapatraRochester$1.2M
- Charanjit RihalRochester$478K
- Amir LermanRochester$465K
- Martha GroganRochester$330K
- Virend SomersRochester$262K
- Francisco Lopez-JimenezRochester$167K
- Ammar KilluRochester$139K
- Allan JaffeRochester$111K
- Robert McBaneRochester$110K
- Michael McGoonRochester$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.